Literature DB >> 20508612

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.

E Weisberg, X Deng, H G Choi, R Barrett, S Adamia, A Ray, D Moreno, A L Kung, N Gray, J D Griffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20508612      PMCID： PMC4010323          DOI： 10.1038/leu.2010.107

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors:  Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

2.  Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

Authors:  Francisco J Adrián; Qiang Ding; Taebo Sim; Anastasia Velentza; Christine Sloan; Yi Liu; Guobao Zhang; Wooyoung Hur; Sheng Ding; Paul Manley; Jürgen Mestan; Doriano Fabbro; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2006-01-15       Impact factor: 15.040

3.  Rational design of inhibitors that bind to inactive kinase conformations.

Authors:  Yi Liu; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2006-07       Impact factor: 15.040

4.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

5.  Crystal structure of the T315I mutant of AbI kinase.

Authors:  Tianjun Zhou; Lois Parillon; Feng Li; Yihan Wang; Jeff Keats; Sarah Lamore; Qihong Xu; William Shakespeare; David Dalgarno; Xiaotian Zhu
Journal:  Chem Biol Drug Des       Date:  2007-09       Impact factor: 2.817

6.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

7.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

8.  Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Authors:  Jianming Zhang; Francisco J Adrián; Wolfgang Jahnke; Sandra W Cowan-Jacob; Allen G Li; Roxana E Iacob; Taebo Sim; John Powers; Christine Dierks; Fangxian Sun; Gui-Rong Guo; Qiang Ding; Barun Okram; Yongmun Choi; Amy Wojciechowski; Xianming Deng; Guoxun Liu; Gabriele Fendrich; André Strauss; Navratna Vajpai; Stephan Grzesiek; Tove Tuntland; Yi Liu; Badry Bursulaya; Mohammad Azam; Paul W Manley; John R Engen; George Q Daley; Markus Warmuth; Nathanael S Gray
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962
  8 in total
  8 in total

1.  Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

Authors:  Ahmet Tunceroglu; Michiyuki Matsuda; Raymond B Birge
Journal:  Mol Cancer Ther       Date:  2010-09-03       Impact factor: 6.261

Review 2.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

Review 3.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

4.  Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.

Authors:  Li-xian Wu; Ying Wu; Rui-jia Chen; Yang Liu; Li-sen Huang; Li-guang Lou; Zhi-hong Zheng; Yuan-zhong Chen; Jian-hua Xu
Journal:  Acta Pharmacol Sin       Date:  2014-02-03       Impact factor: 6.150

Review 5.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

Review 6.  Using NMR to study fast dynamics in proteins: methods and applications.

Authors:  Paul J Sapienza; Andrew L Lee
Journal:  Curr Opin Pharmacol       Date:  2010-10-08       Impact factor: 5.547

7.  The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Authors:  Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701

8.  Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.

Authors:  Michael R Marit; Manprit Chohan; Natasha Matthew; Kai Huang; Douglas A Kuntz; David R Rose; Dwayne L Barber
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.